Related Experiment Video
Updated: Nov 19, 2025
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.1K
Real-world patterns on tumor mutation burden testing in a pan-tumor population
Santosh Gautam1, Sumesh Kachroo2, Richard W DeClue1
1ConcertAI, Memphis, TN 38119, USA.
Future Oncology (London, England)
|January 29, 2021
Summary
Tumor mutational burden (TMB) testing is increasingly used in advanced solid tumors. Patients receiving TMB testing were younger and more likely to be Black, with higher rates of systemic anticancer treatment.
Area of Science:
- Oncology
- Genomics
- Clinical Research
Background:
- Limited real-world data exists on tumor mutational burden (TMB) testing utilization.
- Understanding patient characteristics associated with TMB testing is crucial for clinical decision-making.
Purpose of the Study:
- To investigate the characteristics of patients undergoing tumor mutational burden (TMB) testing.
- To compare patients who received TMB testing with those who did not.
Main Methods:
- Retrospective, observational study design.
- Inclusion of patients aged ≥18 years with advanced solid tumors diagnosed between January 2015 and January 2019.
- Comparison of a TMB testing cohort (n=202) with a non-TMB cohort (n=212).
Main Results:
- The TMB cohort was younger (mean age 62.1 vs. 65.6 years) and had a higher proportion of Black patients (21.3% vs. 11.8%) compared to the non-TMB cohort.
- Systemic anticancer treatment rates were higher in the TMB cohort (91.6%) versus the non-TMB cohort (77.8%).
- Overall clinical characteristics were comparable between the two groups.
Conclusions:
- Significant demographic and treatment differences exist between patients receiving TMB testing and those who do not.
- Further research is warranted to understand the implications of these differences in real-world oncology practice.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.5K
02:07Tumor Progression
6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K